Summit Therapeutics plc Summit Therapeutics Plc : Director/Pdmr Shareholding

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
 
 
   Exercise of Restricted Stock Units and Director Dealings 
 
   Oxford, UK, and Cambridge, MA, US, 19 July 2018 - Summit Therapeutics 
plc (AIM: SUMM, NASDAQ: SMMT), announces the exercise by the following 
Non-Executive Directors of restricted stock units ('RSUs') that entitled 
the holder to subscribe for an ordinary share of one penny nominal value 
at a subscription price of one penny per ordinary share.  The RSUs were 
granted under the Company's 2017 Remuneration Policy and were eligible 
for exercise for a limited time after completion of a vesting period of 
one year. Details of the exercise of the RSUs, all of which took place 
on 18 July 2018, and which have been duly notified to the Company, are 
summarised below. 
 
 
 
 
Director              Position                 RSU's Exercised 
Frank Armstrong       Non-Executive Chairman            41,096 
Barry Price           Non-Executive Director            19,179 
Stephen Davies        Non-Executive Director            19,179 
Leopoldo Zambeletti   Non-Executive Director            19,179 
Valerie Andrews       Non-Executive Director            19,179 
Dave Wurzer           Non-Executive Director            19,179 
Total                                                  136,991 
 
 
   Summit has also been notified that Barry Price and Leopoldo Zambeletti 
have sold 9,851 and 11,286 ordinary shares, at a price of 36.5 pence per 
ordinary share for the two separate transactions, to cover the tax and 
other charges associated with the exercise of the RSUs. 
 
   Following the exercise of the RSUs, the shareholdings of the 
Non-Executive Directors are as follows: 
 
 
 
 
                                            Shareholding     % of Issued Share 
Director             Position             (ordinary shares)       Capital 
                     Non-Executive 
Frank Armstrong       Chairman                      80,538*              0.10% 
                     Non-Executive 
Barry Price           Director                      116,539              0.14% 
                     Non-Executive 
Stephen Davies        Director                      621,660              0.76% 
                     Non-Executive 
Leopoldo Zambeletti   Director                        7,893              0.01% 
                     Non-Executive 
Valerie Andrews       Director                       29,679              0.04% 
                     Non-Executive 
Dave Wurzer           Director                       26,679              0.03% 
Total                                               882,988              1.08% 
 
 
   * Includes shares held by persons closely associated with the director 
 
   Application has been made to the London Stock Exchange for the admission 
of 136,991 ordinary shares to trading on AIM and it is expected that 
admission will become effective and that dealings will commence at 8.00 
a.m. on 24 July 2018. 
 
   Following the exercise of these RSUs, the total number of ordinary 
shares following admission will be 82,125,995 with each ordinary share 
carrying the right to one vote. The Company has no shares in Treasury; 
therefore following admission the total number of voting rights in 
Summit will be 82,125,995. This figure may be used by shareholders as 
the denominator for the calculations by which they will determine if 
they are required to notify an interest in, or change to their interest 
in, the share capital of the Company under the FCA's Disclosure and 
Transparency Rules. 
 
   This announcement contains inside information for the purposes of 
Article 7 of EU Regulation 596/2014 (MAR). 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients, and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for C. 
difficile infection and gonorrhoea and are using our proprietary Discuva 
Platform to expand our pipeline. For more information, visit 
www.summitplc.com and follow us on Twitter @summitplc. 
 
   For more information, please contact: 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)             Tel:    [phone] 
Erik Ostrowski / Michelle Avery (US office)                   [phone] 
 
Cairn Financial Advisers LLP (Nominated Adviser)   Tel:   [phone] 
Liam Murray / Tony Rawlinson 
 
 
   Notification of Transactions pursuant to Article 19(1) of Regulation 
(EU) No. 596/2014 
 
 
 
 
1   Details of the persons discharging managerial responsibilities/person 
     closely associated 
a)  Name 
                              1.    Frank Armstrong 
 
                              2.    Barry Price 
 
                              3.    Stephen Davies 
 
                              4.    Leopoldo Zambeletti 
 
                              5.    Valerie Andrews 
 
                              6.    Dave Wurzer 
2   Reason for the notification 
a)  Position / status 
                              1.    Non-Executive Chairman 
 
                              2.    Non-Executive Director 
 
                              3.    Non-Executive Director 
 
                              4.    Non-Executive Director 
 
                              5.    Non-Executive Director 
 
                              6.    Non-Executive Director 
b)  Initial notification /   Initial notification 
    Amendment 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
a)  Name                     Summit Therapeutics plc 
b)  LEI                      213800NRW8AOMYMTBD89 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
a)  Description of the       Ordinary shares of 1 penny each 
    financial instrument, 
    type of instrument 
 
    Identification code      GB00BN40HZ01 
b)  Nature of the            Exercise of restricted stock units (RSUs) to subscribe 
    transactions              for ordinary shares of one penny nominal value 
c)  Price(s) and volume(s)     Price(s)                           Volume(s) 
                               (i)-(vi) 1p (exercise price) 
                                                                   1.    41,096 
 
 
                                                                   (ii)-(vi) 19,179 
 
d)  Aggregated information 
     - Aggregated volume       136,991 ordinary shares 
     - Price                   1 penny (exercise price) 
e)  Date of the              18 July 2018 
    transactions 
f)  Place of the             Outside a trading venue 
    transactions 
 
 
 
 
1   Details of the persons discharging managerial responsibilities/person 
     closely associated 
a)    Name 
                                1.    Barry Price 
 
                                2.    Leopoldo Zambeletti 
2     Reason for the notification 
a)    Position / status 
                                1.    Non-Executive Director 
 
                                2.    Non-Executive Director 
b)    Initial notification /   Initial notification 
      Amendment 
3     Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
a)    Name                     Summit Therapeutics plc 
b)    LEI                      213800NRW8AOMYMTBD89 
4     Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
a)    Description of the       Ordinary shares of 1 penny each 
      financial instrument, 
      type of instrument 
 
      Identification code      GB00BN40HZ01 
b)    Nature of the            Sale of ordinary shares of one penny nominal value 
      transactions 
c)    Price(s) and volume(s)     Price(s)                Volume(s) 
 
                                  1.    36.5 pence        1.    9,851 
 
                                  2.    36.5 pence        2.    11,286 
 
d)    Aggregated information 
       - Aggregated volume       21,137 ordinary shares 
       - Average Price           36.5 pence 
e)    Date of the              18 July 2018 
      transactions 
f)    Place of the             London Stock Exchange 
      transactions 
 
 
   -END- 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/ 
 

(END) Dow Jones Newswires

July 19, 2018 02:00 ET (06:00 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.